API
< Back to all clusters
[HEALTH] · Italy · 13 sources

started · updated

Italy advances research and treatments for Myasthenia Gravis

Medical experts in Italy are highlighting significant advancements in the treatment and study of Myasthenia Gravis, a rare autoimmune disease that affects the neuromuscular junction, causing muscle weakness and fatigue.

At the 56th Congress of the Italian Society of Neurology, neurologist Nicasio Rini presented findings from a multicenter study involving 14 centers. The research indicates that zilucoplan, a complement inhibitor, effectively improves patients' clinical conditions and quality of life. Notably, the treatment has been associated with a progressive reduction in daily corticosteroid dosages and a drastic decrease in hospitalizations and rescue therapies.

Simultaneously, a new nationwide research initiative called the Poema study has launched. This prospective real-world evidence study involves 40 reference centers and 100 patients across Italy. Led by clinicians including Laura Boffa, the study aims to evaluate the impact of efgartigimod treatment by examining broader dimensions such as psychological well-being, autonomy, and the socio-sanitary impact of the disease over a 12-month period.

Entities

Italian Society of Neurology · Italy · Laura Boffa · Poema study · Policlinico Tor Vergata · Turin

Claims

What the coverage asserts, and how many sources carry each claim.

Sources